# Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

> **NCT00539864** · PHASE3 · COMPLETED · sponsor: **Protein Sciences Corporation** · enrollment: 602 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** FluBlok Influenza Vaccination
- **BIOLOGICAL:** TIV (Fluzone) Influenza Vaccination

## Key facts

- **NCT ID:** NCT00539864
- **Lead sponsor:** Protein Sciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 602 (ACTUAL)
- **Last updated:** 2011-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539864, "Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00539864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*